About Soleno Therapeutics, Inc. - Common Stock (SLNO)
Soleno Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for rare diseases, particularly those associated with genetic and metabolic disorders. The company is committed to addressing significant unmet medical needs by advancing its proprietary treatment candidates through clinical trials. With an emphasis on leveraging cutting-edge science and research, Soleno aims to bring novel solutions to patients suffering from conditions like Prader-Willi syndrome, thereby enhancing their quality of life and overall health outcomes. Read More
NEW YORK and NEW ORLEANS, March 17, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit.
LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive.
Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2026, inclusive (the “Class Period”).
NEW YORK, NY - March 14, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) on behalf of investors that purchased or otherwise acquired Soleno securities between March 26, 2025 and November 4, 2025 (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ:SLNO) securities during the period of March 26, 2025 through November 4, 2025, inclusive (“the Class Period”).
Law Offices of Howard G. Smith reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2026, inclusive (the “Class Period”).
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Soleno Therapeutics, Inc. (“Soleno” or “the Company”) (NASDAQ: SLNO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, NY - March 13, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) on behalf of investors that purchased or otherwise acquired Soleno securities between March 26, 2025 and November 4, 2025 (the “Class Period”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options
